Alessandro Satta
CytotoxicityOncologyAntigenAntibodyApoptosisIn vivoEx vivoT cellImmunosurveillanceImmunotherapyProstate cancerOvarian cancerChimeric antigen receptorRecombinant DNACancer researchMonoclonal antibodyAntigen-presenting cellMedicineImmune systemCancer cell
13Publications
4H-index
54Citations
Publications 9
Newest
BACKGROUND Choline kinase-α (ChoKα/CHKA) overexpression and hyper-activation sustain altered choline metabolism conferring the cholinic phenotype to epithelial ovarian cancer (OC), the most lethal gynecological tumor. We previously proved that CHKA down-modulation reduced OC cell aggressiveness and increased sensitivity to in vitro chemotherapeutics' treatment also affecting intracellular content of one-carbon metabolites. In tumor types other than ovary, methionine decrease was shown to increas...
Source
#1Silvia MartiniH-Index: 3
#2Mariangela FiginiH-Index: 26
Last. Alessandro SattaH-Index: 4
view all 12 authors...
Triple-negative breast cancer (TNBC) is an aggressive disease with poor prognosis and limited therapeutic options. Recent advances in the immunotherapy field have enabled the development of new treatment strategies, among which the use of bispecific antibodies (BsAbs), able to redirect T cells against tumors, has shown promising results. In particular, a BsAb that uses TNF-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) as a target was constructed and demonstrated good results in redirec...
2 CitationsSource
#1A.I. Fraguas-Sánchez (Complutense University of Madrid)H-Index: 7
#2A. Fernández-Carballido (Complutense University of Madrid)H-Index: 14
Last. Ana Isabel Torres-Suárez (Complutense University of Madrid)H-Index: 13
view all 9 authors...
Abstract In this work, we evaluated, for the first time, the antitumor effect of cannabidiol (CBD) as monotherapy and in combination with conventional chemotherapeutics in ovarian cancer and developed PLGA-microparticles as CBD carriers to optimize its anticancer activity. Spherical microparticles, with a mean particle size around 25 µm and high entrapment efficiency were obtained. Microparticles elaborated with a CBD:polymer ratio of 10:100 were selected due to the most suitable release profile...
Source
Background Prostate cancer (PCa) is the second leading cause of cancer-related death in the Western population. The use in oncology of positron emission tomography/computed tomography (PET/CT) with emerging radiopharmaceuticals promises accurate staging of primary disease, restaging of recurrent disease and detection of metastatic lesions. Prostate-specific membrane antigen (PSMA) expression, directly related to androgen-independence, metastasis and progression, renders this tumour associate ant...
5 CitationsSource
#1Alessandro SattaH-Index: 4
#2Giulia GraziaH-Index: 9
Last. Mariangela FiginiH-Index: 26
view all 11 authors...
T-cell-based immunotherapy strategies have profoundly improved the clinical management of several solid tumors and hematological malignancies. A recently developed and promising immunotherapy approach is to redirect polyclonal MHC-unrestricted T lymphocytes towards cancer cells by bispecific antibodies (bsAbs) that engage the CD3 complex and a tumor-associated antigen (TAA). The TNF-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) is an attractive immunotherapy target, frequently expresse...
4 CitationsSource
#1Alessandro SattaH-Index: 4
#2Delia MezzanzanicaH-Index: 35
Last. Mariangela FiginiH-Index: 26
view all 12 authors...
ABSTRACTRecombinant human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or TRAIL-receptor agonistic monoclonal antibodies promote apoptosis in most cancer cells, and the differential expression of TRAIL-R2 between tumor and normal tissues allows its exploitation as a tumor-associated antigen. The use of these antibodies as anticancer agents has been extensively studied, but the results of clinical trials were disappointing. The observed lack of anticancer activity could be attr...
8 CitationsSource
#1Marina BagnoliH-Index: 23
#2Roberta NicolettiH-Index: 8
Last. Delia MezzanzanicaH-Index: 35
view all 13 authors...
Source
#1Barbara FrigerioH-Index: 5
#2Gerben M. Franssen (Radboud University Nijmegen)H-Index: 21
Last. Mariangela FiginiH-Index: 26
view all 12 authors...
// Barbara Frigerio 1 , Gerben Franssen 5 , Elena Luison 1 , Alessandro Satta 1 , Ettore Seregni 2 , Marco Colombatti 3 , Giulio Fracasso 3 , Riccardo Valdagni 4 , Delia Mezzanzanica 1 , Otto Boerman 5 , Silvana Canevari 1,* and Mariangela Figini 1,* 1 Department of Experimental Oncology and Molecular Medicine, S.S. Molecular Therapies, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy 2 S.C. Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy 3 Department o...
9 CitationsSource
#1Alessandro SattaH-Index: 4
#2Delia MezzanzanicaH-Index: 35
Last. Mariangela FiginiH-Index: 26
view all 5 authors...
T cells are the most potent cells of the immune system; however, they fail in the immunosurveillance of tumors. In previous decades, scientists began studying methods to take advantage of T-cell potency in cancer therapy by redirecting them against tumors independently from the T-cell receptor-defined specificity. Among different approaches, the most promising are the use of bispecific antibodies and T-cell engineering to create chimeric antigen receptors. Bispecific antibodies, by simultaneousl...
23 CitationsSource
1
Close Researchers